Illumina Inc at JPMorgan Healthcare Conference Transcript
All right. Good afternoon, everyone. Welcome to our next company presentation by Illumina. I'm Julia Qin, life science tools and diagnostics analyst at JPMorgan. And let me turn the stage over to Francis.
Thanks, Julia, and the JPMorgan team for hosting us, and thank all of you for joining us today. I'm Francis deSouza, the CEO of Illumina.
As a reminder, our presentation today includes forward-looking statements, non-GAAP measures and reconciliations to GAAP measures. Please refer to our SEC filings for a presentation of risks. Also, please review our statements on the hold separate requirement related to GRAIL. GRAIL must be held and operated separately and independently from Illumina pursuant to the interim measures ordered by the European Commission, which prohibited our acquisition of GRAIL.
Today, I'll cover 3 areas in our presentation: first, a company overview, including preliminary 2022 results and 2023 guidance.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |